Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 31, 2015 11:48 PM ET

Biotechnology

Company Overview of KaloBios Pharmaceuticals, Inc.

Key Executives for KaloBios Pharmaceuticals, Inc.

NameBoard RelationshipsTitleAge
Herbert C. Cross No RelationshipsInterim Chief Executive Officer, Interim President and Chief Financial Officer43
Ronald A. Martell 46 RelationshipsExecutive Chairman53
Charles J. Democko No RelationshipsSenior Vice President of Regulatory Affairs and Quality60

KaloBios Pharmaceuticals, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Ronald A. Martell 46 RelationshipsKaloBios Pharmaceuticals, Inc.53
James W. Larrick Ph.D. 42 RelationshipsKaloBios Pharmaceuticals, Inc.--
Raymond M. Withy Ph.D. 7 RelationshipsKaloBios Pharmaceuticals, Inc.60
Denise M. Gilbert Ph.D. 7 RelationshipsKaloBios Pharmaceuticals, Inc.57
Gary A. Lyons 36 RelationshipsRigel Pharmaceuticals, Inc.64
View All Board Members

KaloBios Pharmaceuticals, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee Ph.D.Denise M. Gilbert7 Relationships3 Executives
Compensation Committee Gary A. Lyons36 Relationships3 Executives
Nominating Committee Ph.D.Raymond M. Withy7 Relationships3 Executives
Corporate Governance Committee Ph.D.Raymond M. Withy7 Relationships3 Executives
Advisory Board Ph.D.James W. Larrick42 Relationships1 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$340.0K
340.0K
360.3K
Bonus
Not meaningful
Total Short Term Compensation
Not meaningful
Total Value of Options$340.0K
340.0K
29.9M
Compensation as of Fiscal Year 2014
KaloBios Pharmaceuticals, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

The Procter & Gamble Company Announces Executive Changes
July 28, 2015 9:53 AM ET
Aunt Fannies Appoints Barclay Hope as Board of Advisors
July 13, 2015 1:22 PM ET
Anpath Group, Inc. Elects Arthur R. Batson as Chief Executive Officer and President
July 09, 2015 8:43 PM ET
Katy Industries, Inc. Announces Executive and Management Changes
July 08, 2015 5:13 PM ET
Energizer Holdings, Inc. Announces Management Changes
July 07, 2015 12:31 PM ET

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KaloBios Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.